Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | BRD3 | Q15059 | 8/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148681 | 0.93 | ALOX15 (0.68) | MAPTALOX15SMN1; SMN2MEN1GLA | |
| SCHEMBL4148059 | 0.88 | MAPT (0.63) | MAPTALOX15SMN1; SMN2MEN1GLA | |
| SCHEMBL4147497 | 0.88 | CYP2D6 (0.74) | MAPTALOX15SMN1; SMN2MEN1GLA | |
| SCHEMBL4157241 | 0.88 | ALOX15 (0.59) | MAPTALOX15SMN1; SMN2MEN1GLA | |
| SCHEMBL4147792 | 0.86 | CYP2D6 (0.79) | MAPTALOX15SMN1; SMN2MEN1GLA | |
| SCHEMBL16433488 | 0.86 | ALOX15 (0.58) | MAPTALOX15SMN1; SMN2MEN1GLA | |
| SCHEMBL4148696 | 0.85 | ALOX15 (0.59) | MAPTALOX15SMN1; SMN2MEN1GLA | |
| SCHEMBL4153687 | 0.84 | CYP2D6 (0.56) | MAPTALOX15SMN1; SMN2MEN1GLA | |
| SCHEMBL15577178 | 0.84 | GAA (0.60) | MAPTALOX15SMN1; SMN2MEN1GLA | |
| SCHEMBL4142828 | 0.84 | CYP2D6 (0.79) | MAPTALOX15SMN1; SMN2MEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654228-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | claimed |
| US-7351733-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-01 | — | — | US | claimed |
| US-20060161002-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-20 | — | — | US | claimed |
| US-20090156621-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090156621-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090156621-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-06-18 | — | — | US | disclosed |
| EP-1654228-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1654228-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7351733-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351733-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351733-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060161002-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-20 | — | — | US | disclosed |
| EP-1654228-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2004110999-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156621-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | MAPT 1187/4885ALOX15 1407/4885SMN1; SMN2 4443/4885 |
| US-20060161002-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | HMBS, UGT2B17, TPMT | MAPT 1102/4885ALOX15 939/4885SMN1; SMN2 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.